What's hot
View all perspectives
Dr. John Cush RheumNow
1 year 10 months ago
Watch: Another TYK2 Ticks the Boxes
Dr. Janet Pope discusses late-breaking abstract L12 presented at #ACR23.
https://t.co/1SGuIFOWt6 https://t.co/tb4LRbmfiI
We have known about the VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome for nearly 3 years, but there has been relatively little to say about how to treat it. To date there have been over twice as many publications about VEXAS (263 publications) as there have been patients described with respect to treatment strategies (116 patients). One of the late breaking abstracts may finally have rectified this imbalance.
Should rheumatologists be counseling patients on cervical cancer prevention and screening? The data from Abstract #1479 at ACR Convergence 2023 suggests that this should be an important conversation with our female lupus patients.
Dr. John Cush RheumNow
1 year 10 months ago
#ACR23 – Day 1 Report
The day began with a bang with the Year in Review that featured the sage insights of Drs. Philip Seo and Tomas Mustelin about the scientific and clinical rheumatology highlights from the past year.
https://t.co/a79M2boHRH https://t.co/5P18ybazGK
Richard Conway
1 year 10 months ago
Taylor et al. Novel blood assay for sero+ and sero- RA. Differentiates well from other diseases. May be very valuable for sero- RA diagnosis = sensitivity 83.7%, +LR 21.46, and -LR 0.17. Needs validation. Abstr#2586 #ACR23 @RheumNow https://t.co/jw41F8YohE https://t.co/kXi3km0b07
David Liew drdavidliew
1 year 10 months ago
Last abstract of #ACR23 was #ACRBest
Plasma cfDNA signatures (synovial mapped) to identify RA vs OA, other inflamm arthritis
Great performance, even with seroneg RA
A blood test to:
diagnose
?phenotype
?identify best b/tsDMARD
Could be massive
Peter Taylor ABST2586 @RheumNow https://t.co/tJX2jXV0Oe
Janet Pope
1 year 10 months ago
#ACRbest Yrin Preview @ACRheum
J Bathon
Take home
Symptomatic #Rx of ACPA+ people WITH #DMARD is too late to alter risk of #RA when drug is d/c
AI to read joint erosions on X-ray May be ‘too little too late’
#Steroids in #RA increase #MACE even after d/c
#ACR23 @RheumNow
David Liew drdavidliew
1 year 10 months ago
Identifying GCA diagnosis and disease activity through proteomics from plasma:
diagnosis looks good
disease activity looks harder
(Much like a lot of things in GCA, really)
Exciting work @MayoClinic @MdWarrington @jsung0906 #ACR23 ABST2601 @RheumNow https://t.co/SwxN58LieB
Janet Pope
1 year 10 months ago
#ACR23 Yr in Preview
J Bathon
Shared decision making w tradeoffs showed sex differences for concerns & preferences in #RA present
dependent on how you ask the questions
Unmet needs (I think 🤔)
biomarkers of flare for #inflammatory #arthritis
Rx select’n/retention
@RheumNow
Dr. John Cush RheumNow
1 year 10 months ago
Is MSOT the New Ultrasound?
Dr. Aurelie Najm reports on oral abstract 0750 presented at #ACR23
https://t.co/okbGHTR0i3 https://t.co/9zkHPiFl74
Dr. John Cush RheumNow
1 year 10 months ago
Watch: Assessment and Treatment of Cardiovascular Risks in Rheumatoid Arthritis
Dr. Antoni Chan discusses abstract 0387 and abstract 0391 presented at #ACR23
https://t.co/avnarOGZui https://t.co/4CeAumv31b
Richard Conway
1 year 10 months ago
Greigert et al. IL17 in GCA. Increases vascular inflammation. Synergistic effect on myofibroblasts with IFN-γ - increases IL-1B, IL-6, GM-CSF, CCL20 (recruits T cells), CCL2 (recruits monocytes), VEGF (neoangiogenic). Abstr#2599 #ACR23 @RheumNow https://t.co/p4GumZStAZ https://t.co/zZv0TF4fmn
Dr. Antoni Chan
1 year 10 months ago
Telitacicept a recombinant fusion protein targeting, neutralizing BLyS and APRIL, phase 3 study in RA MTX-IR at 24 wk, ACR20 (60% vs 27% PBO), ACR50 (21% vs 6% PBO), reduced DAS28-ESR, no radiographic progression, Wang L Abst#L20 #ACR23 #ACRBest @RheumNow https://t.co/nuvizqQZsR https://t.co/PRtlea3AqU
Md Yuzaiful Md Yusof
1 year 10 months ago
#ACR23 Abstr#2587 Can we agree on how to measure frailty in #SLE? A cohort study: moderate agreement at best among SLICC-FI, SPPB, FRAIL=>2 & PROMIS PF=<40. SLICC-FI was robust predictor of all outcomes except for cognitive impairment. FRAIL & PROMIS not far behind @RheumNow https://t.co/qWjM4crPvg
Poster Hall